Clinical Trial Update: CCI-779 and Rituximab in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma [Phase 2]

View source ↗

Summary

Phase 2 results for the combination of temsirolimus (CCI-779) and rituximab in relapsed or refractory non-Hodgkin lymphoma have been reported. The study include…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mantle Cell Lymphoma
• Non-hodgkin Lymphoma

Drugs mentioned

• Rituxan (rituximab)
• Torisel (Temsirolimus)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Mantle Cell Lymphoma | Phase 2 | Status: COMPLETED | Results posted: 2014-01-22